Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia

PURPOSE: Following the emergency use authorization of BNT162b2 by the Food and Drug administration (FDA) in early December 2020, mRNA- and vector-based vaccines became an important means of reducing the spread and mortality of the COVID-19 pandemic. The European Medicines Agency labelled immune thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzicka, Michael, Wurm, Sonja, Lindner, Lars, Dreyling, Martin, von Bergwelt-Baildon, Michael, Boeck, Stefan, Giessen-Jung, Clemens, Milani, Valeria, Stemmler, Joachim H., Subklewe, Marion, Weigert, Oliver, Spiekermann, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531644/
https://www.ncbi.nlm.nih.gov/pubmed/36195695
http://dx.doi.org/10.1007/s15010-022-01909-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531644/
https://www.ncbi.nlm.nih.gov/pubmed/36195695
http://dx.doi.org/10.1007/s15010-022-01909-5

Ejemplares similares